Media Contact: Melody Udell
September 15, 2023
Insulin price caps and list price reductions are a huge step forward for patient access. But what will these changes mean for health plans?
September 13, 2013
Rebate leakage drains millions in revenue from pharma companies every year. To ensure contract compliance, manufacturers can implement these five steps.
September 13, 2013
Buy-and-bill remains the most common distribution channel for provider-administered oncology drugs, but pharmacy channels are still significant, especially for hospital outpatient departments.
September 12, 2023
Infusing a commercialization strategy with real-world data provides a more holistic view of the patient journey.
July 1, 2023
Preliminary data indicate that 2023 may prove to be the most volatile year for health plan enrollment in a decade.
May 31, 2023
The shot’s clearance comes several weeks after the regulator made GSK’s Arexvy the first vaccine for RSV in the U.S.
May 15, 2023
Over the past few decades, pharma companies have perfected the art of using market access data to support product launches, negotiate payer discounts, and secure preferred status and positioning.
May 5, 2023
The Senate Health, Education, Labor and Pensions (HELP) Committee went to work this week to find a bipartisan consensus on measures to reduce prescription drug costs.
May 5, 2023
Vaccination is especially important for older adults with any chronic health conditions because vaccines can prevent serious illness and resulting complications down the road.
April 11, 2023
Twelve specialty pharmacies recognized for their dedication to top-quality customer service.
March 13, 2023
By the end of 2023, more than half of the total Medicare population is expected to be enrolled in Medicare Advantage (MA), which has climbed from 25.2 million members in 2020 to 31.5 million members today.
February 22, 2023
Our latest update finds that for 2022, about 40% of commercial lives have adopted these benefit designs.
February 3, 2023
Humira, the best-selling drug used to treat multiple forms of arthritis and other conditions such as ulcerative colitis and Crohn’s disease, finally has some competition.
January 27, 2023
Given the growth of specialty pharmaceuticals, manufacturers will need to develop more aggressive contracting strategies to secure optimal market access for their medical benefit drugs.
January 26, 2023
Health insurance plans and PBMs receive poor grades for ensuring access to medications for patients living with autoimmune diseases, according to a newly released scorecard.
January 24, 2023
DDW Multimedia Editor Megan Thomas observes the 2023 drug discovery landscape, speaking to industry experts and looking at the foundations of 2022 on which next year will lean.
January 17, 2023
While ICER found that overall major payer coverage policies are in line with the organization’s fair access criteria, many payers do not provide adequate transparency into clinical coverage criteria.
October 14, 2022
Next year’s staggered launch of adalimumab biosimilars will mark one of the largest losses of exclusivity for a pharmaceutical company in U.S. market history.
October 3, 2022
When faced with launching its new product, one midsized pharma manufacturer’s marketing team needed an innovative way to quickly identify and geographically target the right cohort of patients for their highly specialized therapy.
August 1, 2022
With the continuation of the COVID-19 pandemic and resulting policy changes, the health plan landscape is facing some complex challenges ahead.
Get the latest news, press releases and event info from MMIT.